期刊文献+

弥漫性大B细胞淋巴瘤免疫表型分类与c-MYC重排的相关性研究 被引量:10

Research on correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma
下载PDF
导出
摘要 目的探讨弥漫性大B细胞淋巴瘤(DLBCL)免疫表型分类与c-MYC重排的相关性。方法根据淋巴瘤细胞免疫标志物CD10、B细胞淋巴瘤原癌基因-6(BCL-6)及多发性骨髓瘤原癌基因-1(MUM-1)的表达情况,将46例DLBCL分为生发中心B细胞样(GCB)与非生发中心B细胞样(non-GCB)2类,用荧光原位杂交(FISH)技术检测GCB类与non-GCB类中c-MYC重排情况。结果 46例标本中共有4例(8.7%)发生c-MYC重排,其中20例GCB类中发现4例(20.0%)c-MYC重排,而26例non-GCB类中未发现c-MYC重排。GCB类和non-GCB类中c-MYC重排差异有统计学意义(P<0.05)。结论 GCB类DLBCL患者c-MYC重排发生率较高,c-MYC重排是一部分GCB类DLBCL预后差的原因。FISH技术能快速、准确、灵敏地检测出c-MYC重排。 Objective To investigate the correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma (DLBCL). Methods According to the lymphoma cell immune marker CD10, B cell lymphoma 6 ( BCL-6 ) and multiple myeloma oncogene 1 ( MUM-1 ) expression levels ,46 cases of DLBCL were classified into germinal center B cell-like (GCB) group and non-germinal center B cell-like (non-GCB) group, c-MYC rearrangement status was analyzed by fluorescence in situ hybridization (FISH) in GCB and non-GCB groups. Results Of the 46 DLBCL eases,4 cases (8.7%) had c-MYC rearrangement. The 4 cases of c-MYC rearrangement belonged to the GCB group. There was no c-MYC rearrangement in non-GCB group. The c-MYC rearrangement had statistical significance between GCB and non-GCB groups ( P 〈 0.05). Conclusions The GCB group in patients with DLBCL has a high c-MYC rearrangement, and c-MYC rearrangement is a poor predictor for a part of GCB group. FISH is a rapid, accurate and sensitive technique for the detection of c-MYC rearrangement.
出处 《检验医学》 CAS 2013年第4期308-311,共4页 Laboratory Medicine
关键词 c-MYC重排 弥漫性大B细胞淋巴瘤 荧光原位杂交 c-MYC rearrangement Diffuse large B-cell lymphoma Fluorescence in situ hybridization
  • 相关文献

参考文献11

  • 1Sabattini E , Bacci F , Sagramoso C, et al. WHOclassification of tumours of haematopoietic andlymphoid tissues in 2008 : an overview [ J ].Pathologica,2010, 102(3):83-87.
  • 2Alizadeh AA,Eisen MB , Davis RE,et al. Distincttypes of diffuse large B-cell lymphoma identified bygene expression profiling [ J ]. Nature, 2000,403(6769) :503-511.
  • 3Hans CP , Weisenburger DD,Greiner TC,et al.Confirmation of the molecular classification of diffuselarge B-cell lymphoma by immunohistochemistryusing a tissue microarray [ J]. Blood,2004,103 ( 1 ):275-282.
  • 4Au WY,Horsman DE,Gascoyne RD,et al. Thespectrum of lymphoma with 8q24 aberrations : aclinical,pathological and cytogenetic study of 87consecutive cases [ J ]. Leuk Lymphoma, 2004,45(3):519-528.
  • 5Sehn LH, Berry B, Chhanabhai M, et al. The revisedinternational prognostic index ( R-IPI) is a betterpredictor of outcome than the standard IPI for patientswith diffuse large B-cell lymphoma treated with R-CHOP[J]. Blood,2007,109(5) :1857-1861.
  • 6Yoon SO,Jeon YK,Paik JH,et al. MYC translocationand an increased copy number predict poor prognosisin adult diffuse large B-cell lymphoma ( DLBCL),especially in germinal centre-like B cell ( GCB) type[J]. Histopathology ,2008 ,53 (2) :205-217.
  • 7Savage KJ, Johnson NA, Ben-Neriah S, et al. MYCgene rearrangements are associated with a poorprognosis in diffuse large B-cell lymphoma patientstreated with R-CHOP chemotherapy[ J]. Blood,2009,114(17) :3533-3537.
  • 8Snuderl M , Kolman OK, Chen YB , et al. B-celllymphomas with concurrent IGH-BCL2 and MYCrearrangements are aggressive neoplasms with clinicaland pathologic features distinct from Burkittlymphoma and diffuse large B-cell lymphoma[ J]. AmJ Surg Pathol,2010,34(3) :327-340.
  • 9Ninan MJ, Wadhwa PD,Gupta P,et al. Prognosticationof diffuse large B-cell lymphoma in the rituximab era[J]. Leuk Lymphoma,2011 ,52(3) :360-373.
  • 10He L, He X, Lim LP, et al. A microRNA componentof the p53 tumour suppressor network [ J ]. Nature,2007,447(7148) :1130-1134.

同被引文献120

引证文献10

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部